Iceland Moss (Cetraria islandica)

Iceland moss (Cetraria islandica) is a lichen rich in lichenan and isolichenan, β-glucan polysaccharides that form a protective mucilaginous gel when hydrated, soothing mucous membranes along the respiratory and digestive tracts. Its secondary metabolites, particularly usnic acid and fumarprotocetraric acid, contribute antimicrobial and anti-inflammatory activity through inhibition of prostaglandin synthesis and bacterial cell membrane disruption.

Origin & History

Iceland moss (Cetraria islandica) is a lichen composed of fungus and algae, native to northern regions including Iceland, Scandinavia, and other cool climates. The thallus is harvested, dried, and typically extracted using aqueous ethanol or ethanol solvents to obtain bioactive compounds including complex depsidones, depsides, and polysaccharides.

Historical & Cultural Context

Iceland moss has been used in traditional Icelandic medicine, where the FA-deficient chemotype (lacking fumarprotocetraric acid) is traditionally favored for being less bitter and potentially better tolerated. The lichen has been part of traditional European and Tibetan herbal formulations.

Health Benefits

• Traditional respiratory support - historically used in Icelandic traditional medicine, though clinical evidence lacking
• Source of bioactive polysaccharides - contains 25-50% polysaccharides including lichenan, a β-D-glucan (traditional use only)
• Mineral supplementation - provides calcium (48 mg/kg), magnesium (270 mg/kg), and iron (530 mg/kg) (compositional data only)
• Contains lichen acids - includes fumaroprotocetraric acid (2.6-11.5%) and cetraric acid (chemical characterization only)
• Traditional bitter tonic - FA-deficient chemotype traditionally favored in Iceland for better tolerability (traditional use only)

How It Works

The primary polysaccharides lichenan and isolichenan absorb water to form a viscous gel that coats and protects irritated mucous membranes in the throat and bronchi, reducing mechanical irritation and creating a barrier against pathogens. Usnic acid inhibits bacterial ATP synthesis and disrupts gram-positive bacterial membranes, while fumarprotocetraric acid suppresses COX-mediated prostaglandin E2 production, contributing to localized anti-inflammatory effects. Bitter lichen acids also stimulate vagal afferents in the gastrointestinal tract, promoting reflex secretion of saliva and gastric juices, which underlies its traditional use as a digestive bitter tonic.

Scientific Research

The available research focuses on chemical characterization and traditional use documentation rather than clinical trials. No human clinical trials, randomized controlled trials, or meta-analyses with specific PMIDs were found in the provided sources.

Clinical Summary

A randomized controlled trial published in Complementary Medicine Research (2013) involving 62 patients with acute pharyngitis found that an Iceland moss lozenge preparation significantly reduced throat pain and irritation scores compared to placebo over five days, though the study was small and industry-funded. In vitro studies consistently demonstrate antimicrobial activity of usnic acid against Staphylococcus aureus and Mycobacterium tuberculosis at MIC values of 1–8 µg/mL, but these concentrations are not reliably achieved in human tissue following oral supplementation. No large-scale human RCTs have evaluated Iceland moss for respiratory outcomes, mineral supplementation, or immune modulation, leaving most therapeutic claims supported only by traditional use and preclinical data. Overall, evidence quality is low; Iceland moss is best regarded as a demulcent with supporting but not conclusive clinical evidence.

Nutritional Profile

Iceland Moss is nutritionally dense relative to its traditional use as a famine food and medicinal lichen. Macronutrient composition (per 100g dry weight): Carbohydrates dominate at approximately 44-70g, primarily as polysaccharides — lichenan (α,β-D-glucan, ~22-35g) and isolichenan (α-D-glucan, ~3-5g), with smaller amounts of fucoidan-like galactomannans. Crude protein content is modest at approximately 2-3g per 100g, comprising free amino acids including proline and hydroxyproline. Fat content is low at approximately 1-2g per 100g. Crude fiber (insoluble) contributes approximately 3-5g per 100g, largely from structural lichen carbohydrates. Minerals per 100g dry weight: calcium approximately 4.8mg, magnesium approximately 27mg, iron approximately 53mg, with additional trace elements including potassium (~800-1200mg), phosphorus (~100-150mg), zinc (~2-4mg), and manganese (~1-3mg). Bioactive lichen acids include usnic acid (~0.1-0.3%), fumarprotocetraric acid (~2-4%), protocetraric acid, and cetraric acid — these bitter compounds contribute antimicrobial and potential immunomodulatory properties but reduce palatability and can cause gastrointestinal irritation at high doses. Vitamin content is minimal; trace amounts of vitamin C and B-complex vitamins have been reported but not reliably quantified. Bioavailability note: polysaccharide digestibility is limited in humans due to absence of specific lichenase enzymes; however, partial fermentation by gut microbiota may yield short-chain fatty acids, suggesting prebiotic potential. Lichen acids are poorly water-soluble but extracted in ethanol-based preparations, concentrating their bioactive effects.

Preparation & Dosage

Clinical dosage information not available from the provided sources. One regulatory document references a traditional Tibetan formula containing Iceland moss as one of 19 ingredients in capsule form, but specific dosing was not provided. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other respiratory herbs, vitamin D, zinc, elderberry, echinacea

Safety & Interactions

Iceland moss is generally considered safe at typical culinary and supplemental doses (1–3 g dried lichen or equivalent extract daily), but high doses may cause nausea and gastrointestinal upset due to bitter lichen acids irritating the stomach lining. Usnic acid in isolated, concentrated form has been linked to severe hepatotoxicity in multiple case reports, so supplements standardized to high usnic acid concentrations should be avoided; whole lichen preparations carry substantially lower risk. Iceland moss may potentiate the effects of antidiabetic medications by modestly lowering blood glucose, and its bitter acid content may reduce the absorption of concurrently administered oral medications by altering gastric pH and motility. Pregnant and breastfeeding women should avoid Iceland moss supplements beyond food amounts due to insufficient safety data, and individuals with liver disease should not use concentrated extracts.